Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8535189 | 0.81 | KMT2A (0.68) | KMT2AL3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL5315001 | 0.78 | GSR (0.46) | KMT2AL3MBTL1MMP2MMP9MMP8 | |
| SCHEMBL27481214 | 0.77 | KMT2A (0.43) | KMT2AL3MBTL1MAPTALDH1A1HTT | |
| SCHEMBL5310617 | 0.77 | HAO1 (0.43) | HAO1KMT2APLK1TAS1R3TAS1R1 | |
| SCHEMBL19659999 | 0.74 | L3MBTL1 (0.60) | KMT2AL3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL10848459 | 0.74 | HAO1 (0.51) | HAO1KMT2APLK1TAS1R3TAS1R1 | |
| SCHEMBL22281608 | 0.73 | L3MBTL1 (0.64) | KMT2AL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22281426 | 0.73 | GSK3B (0.61) | KMT2AL3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL17290731 | 0.73 | PLK1 (0.53) | HAO1KMT2APLK1TAS1R3TAS1R1 | |
| SCHEMBL5768900 | 0.73 | HAO1 (0.58) | HAO1KMT2APLK1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004053-B1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3004053-B1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| US-10435363-B2 | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | CADILA HEALTHCARE LIMITED (IN) | 2019-10-08 | — | — | US | disclosed |
| US-10435363-B2 | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | CADILA HEALTHCARE LIMITED (IN) | 2019-10-08 | — | — | US | disclosed |
| US-10112898-B2 | Process for the preparation of saroglitazar pharmaceutical salts | CADILA HEALTHCARE LIMITED (IN) | 2018-10-30 | — | — | US | disclosed |
| US-20170144968-A1 | PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2017-05-25 | — | — | US | disclosed |
| US-20170144968-A1 | PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2017-05-25 | — | — | US | disclosed |
| US-20170144968-A1 | PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2017-05-25 | — | — | US | disclosed |
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2016-07-07 | — | — | US | disclosed |
| US-20160107989-A1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2016-04-21 | — | — | US | disclosed |
| US-20160107989-A1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2016-04-21 | — | — | US | disclosed |
| EP-3004053-A2 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | Cadila Healthcare Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| WO-2015033357-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015033357-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2015-03-12 | — | — | WO | disclosed |
| WO-2014195967-A2 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2014-12-11 | — | — | WO | disclosed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194280-A1 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | HPD, HMGCR, CYP51A1 | HAO1 799/4885KMT2A 965/4885PLK1 1849/4885 |
| US-20160107989-A1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CYP51A1, DHCR7, LIPA | HAO1 1178/4885KMT2A 2536/4885PLK1 1212/4885 |
| US-20170144968-A1 | PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CYP51A1, LIPA, DHCR7 | HAO1 1312/4885KMT2A 2414/4885PLK1 1269/4885 |
| US-10435363-B2 | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | CYP51A1, LIPA, DHCR7 | HAO1 1312/4885KMT2A 2414/4885PLK1 1269/4885 |
| US-10112898-B2 | Process for the preparation of saroglitazar pharmaceutical salts | DPP4, CYP51A1, TPP1 | HAO1 855/4885KMT2A 1079/4885PLK1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.